During osteoporosis bone formation by osteoblasts is reduced and/or bone resorption by osteoclasts is enhanced. Currently, only a few factors have been identified in the regulation of bone integrity by osteoblast-derived osteocytes. In this study, we show that specific disruption of menin, encoded by multiple endocrine neoplasia type 1 (Men1), in osteoblasts and osteocytes caused osteoporosis despite the preservation of osteoblast differentiation and the bone formation rate. Instead, an increase in osteoclast numbers and bone resorption was detected that persisted even when the deletion of Men1 was restricted to osteocytes. We demonstrate that isolated Men1-deficient osteocytes expressed numerous soluble mediators, such as C-X-C motif chemokine 10 (CXCL10), and that CXCL10-mediated osteoclastogenesis was reduced by CXCL10-neutralizing antibodies. Collectively, our data reveal a novel role for Men1 in osteocyte-osteoclast crosstalk by controlling osteoclastogenesis through the action of soluble factors. A role for Men1 in maintaining bone integrity and thereby preventing osteoporosis is proposed.
The maintenance of bone mass is severely affected in osteoporotic patients and other bone disorders and can have multiple etiologies. The complex communication of boneforming osteoblasts, bone-residing osteocytes, and boneresorbing osteoclasts is still not fully understood. Two hallmark studies 1, 2 have demonstrated that osteocytes are the major source of the osteoclastogenesis-stimulating factor RANKL and thus key components in the control of bone mass. This property goes beyond their previously suggested function of sensing the mechanical loading of bone. 3 PTH 4 and sclerostin 5 have been reported to stimulate osteocytes to support osteoclastogenesis via a RANKL-dependent pathway. High-mobility group box 1 (HMGB1), which is chemotactic to osteoclasts, is enhanced in apoptotic MLO-Y4 cells; 6 however, there is little information on other factors controlling osteoclast activity by osteoblast-derived osteocytes.
The nuclear protein menin encoded by the gene Men1 (multiple endocrine neoplasia type 1) has recently been suggested to control bone mass at higher age through its influence on the differentiation and function of osteoblasts. 7 In vitro studies in cell lines and primary osteoblasts derived from 6-month-old mice showed that menin promotes early osteoblast differentiation in committed cells. Knockdown of Men1 with antisense oligonucleotides lead to enhanced BMP2 signaling [8] [9] [10] and to facilitated inhibition of the late stage of osteoblast differentiation by potentiating TGFβ-dependent Smad3 signaling. 11, 12 Accordingly, reduced bone mass and reduced bone formation due to decreased osteoblast proliferation and differentiation and enhanced apoptosis have been reported using aged osteocalcin-cre mice crossed to Men1 floxed mice that leads to a conditional deletion of menin in the late stage of differentiated osteoblasts. 7 On the other hand, aged osteoblast-specific menin transgenic mice were found to display increased bone mass. 7 However, whether Men1 plays a role in bone cells to control bone integrity in young or middle-aged mice is completely unknown.
Using multiple cre-lines, we comprehensively analyzed the effects of loss of function of menin throughout the osteoblast lineage, in osteoclasts, and in osteocytes on bone integrity. Furthermore, we identified genes under the control of Men1 responsible for the osteocyte-dependent regulation of osteoclast formation.
Results
Men1 disruption in the osteoblast lineage severely affects bone mass but not the bone formation rate. In order to address the role of Men1 in the entire osteoblast lineage including osteocytes in vivo, we generated mice lacking Men1 specifically in the osteoblast lineage by , and trabecular separation (Tb.Sp.) (e) were measured from distal femurs of female Men1 flox and Men1 Runx2Cre mice at indicated age by micro CT (n = 4 or 5). *Po0.05, **Po0.01, ***Po0.001. (f and g) Primary calvarial osteoblasts were isolated from Men1 flox and Men1 gtRosaCreERT2 mice. After pretreatment with 4-OHT to allow recombination of the Men1flox allele, cells were cultured with or without osteogenic induction (OI) medium in the absence or presence of BMP2 for 7 and 12 days and stained for alkaline phosphatase (f) and alizarin red (g), respectively. (h-j) mRNA expression levels of Alpl (h) and Sp7 (i) from 7-day-treated cells as in (f), and Bglap (j) from 12-day-treated cells as in (g) were analyzed by QRT-PCR (n = 5). *Po0.05, **Po0.01, ***Po0.001 versus untreated Men1 flox . (k and l) Fluorescent micrographs of dual calcein labeling (k) and its quantitative analysis of bone formation rate per bone surface (BFR/BS) (l) by dynamic histomorphometry in femurs of 12-week-old female Men1 flox and Men1 Runx2Cre mice (n = 4 or 5). (m) Determination of the serum PINP level (a bone formation marker) in 12-week-old female Men1 flox and Men1 Runx2Cre mice (n = 5). Data are represented as mean ± S.E.M.
crossing Men1 tm1.1Zqw (hereafter designated Men1 flox ) mice 13 to Tg(Runx2-icre)1Jtuc (hereafter designated Runx2Cre) mice 14 to obtain Men1 Runx2Cre mice. Immunohistochemistry of femurs indicated a decreased menin expression in osteoblasts and osteocytes of Men1 Runx2Cre mice (Supplementary Figure S1a ). Successful recombination was additionally confirmed by crossing a Rosa mT/mG (Tomato/ EGFP) reporter mouse 15 to Runx2Cre mice and demonstrating cre-loxP recombination by GFP-positive osteoblasts and osteocytes (Supplementary Figure S1b ). Men1 Runx2Cre mice were viable without gross alterations of the skeleton (Supplementary Figure S1c ) and were born slightly below the Mendelian ratio ( Supplementary Table S1 ).
Strikingly, micro computed tomography (micro CT) revealed a strong bone loss in the distal femur of female Men1 Runx2Cre mice (Figures 1a-e ). This bone loss was observed in 4-weekold mice and persisted upon aging (Figures 1b-e ). Similarly, bone loss was observed in male Men1 Runx2Cre mice ( Supplementary Table S2 ), resembling osteoporosis. Although trabecular thickness remained unaltered, the strong decrease of trabecular bone mass in Men1 Runx2Cre mice was found to be caused by a low number of trabeculae and an increased trabecular separation (Figures 1b-e and  Supplementary Table S2 ). Notably, cortical bone thickness in the femur was unchanged ( Supplementary Table S3 ). Supplementary Table S2 ). Next, we analyzed whether the osteoporotic phenotype was specifically dependent on the elimination of Men1 in the osteoblast lineage.
Histomorphometry and micro CT analysis of tibiae and vertebrae confirmed the trabecular bone loss (Supplementary Figures S1d-h and
First, we corroborated that the observed bone loss strictly depended on elimination of Men1 in the osteoblast lineage. Mice with a disruption of Men1 in the myeloid lineage (Lyz2 tm1(cre)Ifo , 16 Figures S2c-f ). In contrast, eliminating Men1 in the early differentiated osteoblast lineage using another osteoblast-specific cre-line, Tg(Sp7-tTA,tetO-EGFP/ cre)1Amc (hereafter designated OsxCre) mice, 17 reproduced the severe osteoporosis as observed in Men1 Runx2Cre mice. The resulting Men1 OsxCre mice also displayed a strong decrease of trabecular bone volume and trabecular numbers and an increased trabecular separation, whereas trabecular thickness was only slightly affected ( Supplementary Table S2 ).
Second, we asked whether loss of Men1 influenced the expression of osteoblast marker genes and osteoblast numbers in vivo. The mRNA expression of osteoblast marker genes such as Alpl, Col1a1, Runx2, and Bglap was similar in the calvarial bone of Men1 Runx2Cre mice compared with control (Men1 flox ) ( Supplementary Figures S3a-d ). In line with this, dynamic histomorphometry of vertebrae did not detect significant changes of osteoblast numbers and osteoblast surface ( Supplementary Figures S3e and f ). Osteocyte number was significantly higher in Men1 Runx2Cre mice (Supplementary Figure S3g ). Furthermore, we asked whether Men1 deficiency could influence osteoblast differentiation in vitro as suggested in previous studies. 7, 12 To eliminate Men1 efficiently in osteoblast progenitor cells, we cultivated mesenchymal progenitor cells and primary calvarial osteoblasts derived from Men1 flox mice crossed to a mouse line with ubiquitous expression of a Cre-ERT2 fusion protein (Gt(ROSA)26Sor tm9(Cre/ESR1)Arte , hereafter designated gtRosaCreERT2), allowing a dramatic decrease in Men1 expression upon tamoxifen treatment ( Supplementary Figures S3o, p , and s). Disruption of Men1 in vitro did not affect the growth of calvarial osteoblasts (Supplementary Figure S3h) . Intriguingly, the differentiation of Men1-deficient calvarial osteoblasts and mesenchymal progenitor cells was unaffected and the cells responded normally to BMP2-induced differentiation as indicated by histochemical staining ( As it was previously reported that inhibiting Men1 expression with antisense oligonucleotides could affect TGFβ signaling, 11 we also analyzed the TGFβ-induced phosphorylation of Smad3 as well as the expression of TGFβ-induced genes in the absence of Men1 in osteoblasts. No significant difference was found at the level of Smad3 phosphorylation, nor at expression levels of the TGFβ target genes Serpine and Skil in the absence of Men1 ( Supplementary Figures S3s-u) .
In accordance with the unaltered osteoblast differentiation, there was no difference in the bone formation rate in femurs (Figure 1m ). However, the bone formation rate in 12-month-old Men1 Runx2Cre mice was significantly reduced ( Supplementary Figures S3x and y) . This corroborates the finding of Kanazawa et al. 7 who described impaired osteoblast function in 9-and 12-month-old mice in which Men1 was eliminated by an osteocalcin-cre.
In summary, despite a possible role for Men1 in bone formation during aging, no drastic changes of osteoblast marker gene expression, osteoblast number, and osteoblast function were observed in young and middle-aged mice lacking Men1 in the osteoblast lineage.
Men1 deficiency in the osteoblast lineage, specifically in osteocytes, leads to an enhanced osteoclastogenesis. Figures S4a and b) . These increases were also seen in calvaria ( Supplementary Figures S4c-e ) and were associated with a high porosity (Supplementary Figure S4f ). Bone resorption as determined by serum C-terminal telopeptide (CTX) level was increased in 12-week-old Men1 Runx2Cre mice (Figure 2c ). To test whether Men1-deficient osteoblasts could cause greater osteoclastogenesis, we performed osteoblast-osteoclast co-culture by using control or Men1-deficient osteoblasts and wild-type osteoclast precursors. Surprisingly, the Men1-deficient osteoblasts could not trigger higher osteoclast numbers ( Figure 2d ).
We observed a strong increase of osteoclast numbers and surface in femurs (Figures 2a and b) and vertebrae (Supplementary
Osteocytes were recently established as major producers of RANKL in bone and therefore important regulators of osteoclastogenesis. 1, 2 As deletion of Men1 by the cre-loxP system in osteoblasts also affects Men1 expression in osteocytes ( Supplementary Figures S1a and b ), we further tested the capacity of Men1-deficient osteocytes to stimulate osteoclast formation ex vivo. To this end, we isolated primary osteocyte-enriched fractions from Men1 gtRosaCreERT2 mice. These cells expressed higher Dmp1 and lower Alpl levels when compared with primary osteoblasts, confirming the efficacy of the isolation of osteocytes (Supplementary Figures  S5a and b ). Following 4-hydroxytamoxifen (4-OHT) treatment to eliminate the Men1 gene (Supplementary Figure S5c) , the osteocyte-enriched fraction was co-cultivated with wild-type bone marrow cells (BMCs) containing osteoclast progenitor cells. As a result, osteoclast number and osteoclast area were significantly higher in the co-culture containing Men1-deficient osteocytes (Figures 2e-g).
Men1 deficiency in osteocytes leads to an enhanced osteoclastogenesis in vivo. The in vitro co-culture experiments suggested that the increased osteoclast number in the mice lacking Men1 in the osteoblastic lineage was conferred by Men1-deficient osteocytes rather than osteoblasts. To confirm this hypothesis in vivo, we generated mice lacking Men1 in osteocytes, but not in early differentiated osteoblasts, by crossing Men1 flox mice to Tg(Dmp1-cre)1Jqfe (hereafter designated Dmp1Cre) mice 18 to obtain Men1 Dmp1Cre mice. Loss of menin in osteocytes in Men1 Dmp1Cre mice was confirmed by immunohistochemistry (Supplementary Figure S5d ) and by crossing Men1 Dmp1Cre mice to Rosa mT/mG reporter mice that displayed a strongly diminished Men1 expression in GFP-positive cells (Figure 3a and Supplementary Figure S5e ). As Dmp1 is also expressed in mature osteoblasts, we stained osteocalcin as a mature osteoblast marker in Men1 Dmp1Cre ; Rosa mT/mG reporter mice (Supplementary Figure S5f) to determine the degree of recombination in these cells. We found that 29 ± 9% of osteocalcin-stained mature osteoblasts were EGFP positive, indicating that a minor fraction of the late-stage differentiated osteoblasts is also mutant in addition to osteocytes in Supplementary Figures S5g and h) . Thus, a similar bone phenotype was observed in Men1 Dmp1Cre mice as shown in Men1 Runx2Cre and Men1 OsxCre mice. Together with the observed increase of osteoclastogenesis by osteocytes, these observations strongly suggest that osteoporosis by loss of Men1 is executed by osteocytes in these three different conditional knockout mouse strains.
Menin suppresses CXCL10 to regulate osteocyte-osteoclast crosstalk. We could not detect differences in Tnfsf11 (RANKL) and Tnfrsf11b (OPG) expression in the bone of Men1 Dmp1Cre mice ( Supplementary Figures S6a and b ). We therefore tested whether other soluble factors derived from Men1-deficient osteocytes affected osteoclastogenesis. Transfer of conditioned medium from cultured Men1-deficient osteocyte-enriched fractions to wild-type osteocyte-enriched fractions/osteoclast co-cultures revealed a higher osteoclast formation than the transfer of medium from wild-type osteocyte-enriched fractions (Figures 4a-c) . Furthermore, the conditioned medium from osteocyte-enriched fractions was added to wild-type osteoclast cultures. Again, the conditioned medium from Men1-deficient osteocyteenriched fractions triggered higher osteoclast formation than the medium from control osteocyte-enriched fractions ( Supplementary Figures S6c-e ).
Our findings from the transfer of conditioned medium suggested that the presence of soluble factors derived from osteocytes lacking Men1 influenced osteoclastogenesis. Subsequently, we performed a microarray analysis with the mRNA of osteocyte-enriched fractions (Figures 4d-f ). In total, 2288 differentially expressed genes were found (Figure 4d ). Of these, 775 genes (Figure 4e ) were annotated as secreted factors analyzed by DAVID bioinformatics resources. 19 Of the 775 genes, 81 were upregulated in wild-type osteocytes and 30 were more highly expressed in Men1-deficient osteocyteenriched fractions (Figure 4f , e and Supplementary Table S4 ). Among these 111 genes, 12 were related to osteoclastogenesis based on the literature. All of the 12 osteoclastogenesisassociated genes were subsequently analyzed for their expression in entire calvarial bone of Men1 Dmp1Cre mice by QRT-PCR (Figure 4g and Supplementary Figures S6f-p ). Of these genes, C-X-C motif chemokine 10 (CXCL10), a previously described osteoclastogenesis-inducing factor, 20 showed the most strikingly elevated expression in entire calvarial bone of Men1 Dmp1Cre mice (Figure 4g ). We also detected enhanced CXCL10 secretion in supernatant medium of organ cultures of calvarial bones (Figure 4h ). Real-time PCR confirmed a significantly higher Cxcl10 expression in Men1- neutralizing antibodies did not affect wild-type osteocyteenriched fractions co-cultured with BMCs ( Supplementary  Figures S6r and s) . In order to assess the resorption ability in vitro, the co-cultures were performed on bone slices. Co-cultures with Men1-deficient osteocyte-enriched fractions displayed a clear tendency of higher resorption pit area and significantly increased CTX release that were significantly reduced by the CXCL10-neutralizing antibodies (Figures 5d-f) .
We verified these findings in organ cultures of calvaria derived from Men1 Dmp1Cre mice. TRAP staining, osteoclast marker expression, and the level of resorption marker CTX in the supernatant were all decreased upon CXCL10-neutralizing antibody treatment (Figures 5g-j) , indicating that CXCL10 mediates increased osteoclastogenesis and resorption in intact bones.
Furthermore, CXCL10-neutralizing antibodies were subcutaneously injected over the calvaria of Men1 flox and Men1 Dmp1Cre mice. Osteoclast indicating TRAP staining was reduced in CXCL10-neutralizing antibody-treated Men1 Dmp1Cre mice (Figure 5k ). Osteoclast marker expression was also reduced in the calvaria of these mice (Figures 5l  and m) . Thus, these data demonstrate the reduction of enhanced osteoclastogenesis in Men1 Dmp1Cre mice by CXCL10-neutralizing antibodies in vivo.
In summary, Men1 deficiency specifically in osteocytes increases Cxcl10 expression and enhances osteoclastogenesis in vitro and in vivo that contributes to the osteoporotic phenotype observed in mice with a disruption of Men1 in osteoblast-derived osteocytes (Men1 Runx2Cre , Men1 OsxCre , and Men1 Dmp1Cre mice).
Discussion
In this study, we uncover the role of Men1 in maintaining bone integrity via osteocyte-osteoclast crosstalk. Men1 deficiency in the osteoblast lineage does not affect bone formation, whereby Men1 deficiency in osteocytes promoted osteoclastogenesis by enhancing the production of soluble factors, such as CXCL10, causing osteoporosis in young or middleaged mice.
In agreement with a previous study, 7 we observed a decrease of bone formation in aged 12-month-old female mice. Strikingly, in middle-aged mice, we unequivocally show that selective Men1 deletion in the osteoblastic lineage in three distinct conditional Men1 mutant mouse lines does not alter bone formation, as indicated by the bone formation rate in femurs and vertebrae as well as systemic PINP levels. Our conclusion is supported by the ex vivo analysis of osteoblast differentiation in the absence of Men1 in uncommitted mesenchymal stromal cells and neonatal calvarial osteoblasts. In primary uncommitted mesenchymal stromal cells from 6-to 8-week-old mice and neonatal calvarial osteoblasts from 3-to 5-day-old newborn mice with an efficient deletion of Men1 using an inducible cre-loxP system, we did not detect any differences in osteoblast proliferation and their differentiation potential. This is in contrast to previous studies by Kanazawa et al. 7 who described a decreased osteoblast differentiation of primary calvarial cells derived from 6-monthold Men1flox-osteocalcin-cre mice. In addition, previous studies suggested a decrease of BMP2-Smad1/5/8 signaling and an increase of TGFβ signaling upon abrogation of Men1. 7, 11, 12 In osteoblast progenitor cells with a complete elimination of Men1, no major difference was evident in either Smad1/5/8 phosphorylation or Smad3 phosphorylation upon BMP2 and TGFβ stimulation, respectively. Furthermore, the response of BMP2 and TGFβ target genes was unaltered and, importantly, the effect on osteoblast differentiation was unchanged in calvarial and mesenchymal stromal cells. These discrepancies may be explained in part by the fact that antisense oligonucleotides were used in the in vitro studies, 7,11,12 a technology associated with many undefined off-target effects. The primary cells analyzed by Kanazawa et al. 7 were derived from aged calvaria and we cannot exclude the possibility that such old cells devoid of Men1 display a different response. In summary, our findings support the lack of alterations in osteoblast numbers and the bone formation rate seen in 3-month-old Men1 Runx2Cre mice in vivo.
In this study, we show a novel role for Men1 in osteocytes governing bone resorption. Osteocytes were recently identified as the major source of RANKL in adult mice that is essential for bone resorption. 1, 2 We found in the absence of Men1 in osteoblasts an increased osteocyte number that was also observed in Men1flox-osteocalcin-cre mice. 7 However, in Men1 Dmp1Cre mice, osteocyte numbers were unaltered, indicating that Men1 within osteocytes does not affect the abundance of these cells. Nonetheless, in Men1 Dmp1Cre mice, despite unaltered RANKL expression, we also observed enhanced osteoclast numbers and enhanced resorption based on increased CTX levels in the serum and co-cultures of Men1-deficient osteocyte-enriched fractions with osteoclasts. Given that bone mass is already substantially reduced, the elevated levels of CTX indicate a massive enhanced resorption activity in the remaining bone. This was not due to an intrinsic effect of Men1 in osteoclasts, as there is no recombination in osteoclasts in Runx2Cre, 14 OsxCre, 17 and Dmp1Cre mice. 18 Accordingly, Men1 LysMCre mice exhibiting a loss of Men1 in myeloid cells displayed a normal bone phenotype, confirming that bone mass is not affected by Men1 in osteoclasts.
However, because of the fact that Dmp1Cre recombination occurs in osteocytes as well as in 29 ± 9% of late-stage osteoblast populations 1 (Supplementary Figure S5f) , we cannot fully exclude a possible contribution of Men1-deficient osteoblasts to the enhanced osteoclastogenesis. However, the failure of Men1-deficient osteoblasts, in contrast to Men1deficient osteocyte-enriched fractions, in enhancing osteoclastogenesis and resorptive activity in co-cultures favors a dominant role of Men1 in osteocytes in suppressing osteoclastogenesis in vivo. This is further supported by enhanced release of several soluble factors from Men1-deficient osteocytes as being a causative determinant for enhanced osteoclastogenesis. For example, conditioned medium derived from Men1-deficient osteocyte-enriched fractions displayed an enhanced osteoclastogenic potential, revealing for the first time the role of osteocyte-secreted factors in causing greater osteoclastogenesis. The annotation toward secreted factors from an RNA expression profile defined a potential secretome containing candidate genes important for osteocyte-osteoclast crosstalk beyond the regulation of RANKL. Among those identified, CXCL10 was found as most strongly induced in entire bone because of a dramatic upregulation found in enriched osteocyte fractions. CXCL10 has been reported to stimulate osteoclast differentiation. 20 Furthermore, the menininteracting partner MLL regulates Cxcl10 expression in macrophages and this effect can be abrogated using an MLL-menin inhibitor. 21 We found a clear negative regulation of Cxcl10 expression by Men1, as it was elevated in primary osteocytes and bones from Men1 Dmp1Cre mice and Men1 Runx2Cre mice and reduced in Men1-overexpressing MLO-Y4 osteocyte cells. The functional relevance of enhanced Cxcl10 expression was demonstrated by CXCL10-neutralizing antibody treatment of (1) co-cultures, (2) calvarial organ cultures, and (3) mice that resulted in decreased osteoclast formation and resorption as indicated by decreased TRAP staining, osteoclast marker gene expression, and CTX levels. Our data underscore a crucial role of menin in the negative regulation of Cxcl10 transcription that could be, at least partially, the molecular basis of the enhanced osteoclastogenesis triggered by Men1 disruption in osteocytes. Given that MDX-1100, an antibody against CXCL10, is in clinical trial phase II for treatment of arthritic patients, 22 this may prove to be an attractive agent to improve bone quality.
Despite the general role of Men1 in bone integrity, Men1 conditional knockout mice allow the elucidation of the intrinsic consequences of loss of MEN1 that might occur in patients suffering from MEN1. The osteopenic phenotype of these patients may be masked by their PTH oversecretion. Intriguingly, following parathyroidectomy, bone recovery is worse in MEN1 patients than in other hyperparathyroidism conditions. 23 Our findings will encourage future analyses on possible mutations in the osteoblastic lineage of MEN1 patients that will enable the PTH effects and osteocyte cellautonomic effects on bone integrity to be distinguished.
In conclusion, we have established a novel regulatory axis of osteocyte-osteoclast crosstalk regulated by the tumor suppressor gene Men1. Men1 acts in osteocytes to protect trabecular bone mass by modulation of osteoclast function. A Men1-regulated chemokine, CXCL10, was identified as an osteocyte-osteoclast crosstalk factor. Modulating Men1-regulated factors in osteocytes might serve as a novel molecular base to develop therapeutic strategies to treat osteoporosis.
Materials and Methods
Mice. All mice were kept under standardized conditions with water and food ad libitum in specialized pathogen-free animal facilities at the University of Ulm. Procedures for performing animal experiments were in accordance with and approved by the authorities for ethical permission (the Regierungspräsidium in Tübingen, Germany). Men1 Runx2Cre , Men1 OsxCre , Men1 gtRosaCreERT2 , Men1 LysMCre , Men1 Dmp1Cre , Men1 Dmp1Cre × Rosa mT/mG , and Runx2Cre × Rosa mT/mG mice were generated by intercrossing Men1 flox mice 13 with Tg(Runx2-icre)1Jtuc mice, 14 Tg (Sp7-tTA,tetO-EGFP/cre)1Amc mice, 17 C57BL/6-Gt(ROSA)26Sor tm9(Cre/ESR1)Arte mice (Taconic Artemis, Köln, Germany), Lyz2 tm1(cre)Ifo mice, 16 Tg(Dmp1-cre)1Jqfe mice, 18 and Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/J mice, 15 
, respectively
Micro computed tomography. Femurs, tibiae, and lumbar vertebrae were analyzed using a SkyScan 1174 compact micro CT or SkyScan 1176 in vivo micro CT (Bruker, Billerica, MA, USA) equipped with an X-ray tube working at 50-80 kV/100 μA. Resolution was 6-9 μm, rotation step was set at 0.40°or 1°, and a 0.5 mm aluminum filter was used. For reconstruction of femurs, the region of interest was defined 0.3 mm from the distal growth plate into the diaphysis spanning 1.8 mm. Trabecular bone volume/tissue volume (BV/TV), trabecular thickness (Tb.Th.), trabecular separation (Tb.Sp.), trabecular number (Tb.N.), cortical thickness (Cs.Th.), cortical closed porosity, and cortical bone perimeter (B.Pm.) were determined according to the guidelines issued by the ASBMR Histomorphometry Nomenclature Committee. 24, 25 Histomorphometry. Static and dynamic histomorphometry was performed on undecalcified and decalcified lumbar vertebral and femoral sections of mice receiving dual calcein (Sigma-Aldrich, St. Louis, MO, USA) i.p. injections, as described previously. 25, 26 Osteomeasure software was used for analysis (Osteometrics, Decatur, GA, USA).
Osteoblast differentiation from stromal and calvarial cells. Stromal cells were isolated from inguinal white adipose tissue of Men1 gtRosaCreERT2 mice (6-8 weeks) by digestions for 30 min at 37°C in isolation buffer containing 100 mM HEPES (Sigma-Aldrich), 120 mM NaCl (Merck, Darmstadt, Germany), 4.8 mM KCl (Sigma-Aldrich), 1 mM CaCl 2 •2H 2 O (Sigma-Aldrich), 4.5 mM glucose (Merck), 1.5% albumin (Sigma-Aldrich), and 0.2% collagenase II (Roche, Rotkreuz, Switzerland). The stromal vascular fraction was collected after filtration and centrifugation and subsequently cultivated as described for calvarial cells below.
Bone marrow stromal cells were isolated from femur and tibia of Men1 gtRosaCreERT2 mice (6-8 weeks). Bone marrows were flushed out and cells were seeded at a density of 1 × 10 6 cells per cm 2 . After 72 h, cells were washed three times with medium (DMEM containing 20% fetal bovine serum and 1% penicillin/streptomycin) and subsequently cultivated as described for calvarial cells below.
Primary osteoblasts isolated from calvaria of neonatal Men1 gtRosaCreERT2 mice (postnatal days 3-5) by sequential digestions were cultivated as previously described. 14 The cells were exposed to 1 μM 4-OHT (Sigma-Aldrich) for 3 days and subsequently subjected to osteogenic induction medium (α-MEM containing 10% fetal bovine serum and 1% penicillin/streptomycin, supplemented with 100 mg/ml sodium ascorbate and 5 mM β-glycerophosphate; Sigma-Aldrich) and/or 100 ng/ml hBMP2 (R&D Systems, Minneapolis, MN, USA). Osteoblast differentiation was determined by alkaline phosphatase and alizarin red (both from Sigma-Aldrich) staining at indicated time points.
Osteoclast differentiation. BMCs were isolated from femurs of 2-to 3-month-old mice and 200 000 cells (diameter 45 μm) were seeded per well in 96-well plates. Differentiation of osteoclasts was performed in α-MEM containing 10% fetal bovine serum and 1% penicillin/streptomycin, supplemented with 50 ng/ml RANKL (PeproTech, Rocky Hill, NJ, USA) and 20 ng/ml M-CSF (R&D Systems) for 5 or 7 days, with the medium changed every 2 or 3 days. TRAP staining was performed using a TRAP-kit (Sigma-Aldrich) and TRAP-positive cells with more than three nuclei were counted as osteoclasts. Osteoclast area was quantified using Osteomeasure software.
For conditioned medium-transfer experiments, conditioned medium from Men1deficient primary osteocyte-enriched fractions or control primary osteocyte-enriched fractions was diluted 1:1 in culture medium.
Osteocyte
isolation. Primary osteocyte-enriched fractions from Men1 gtRosaCreERT2 mice were isolated as previously described. 27 Osteocytes were extracted by sequential digestions with collagenase and EDTA (AppliChem, Darmstadt, Germany). Fractions 3-5 of the sequential digest were considered as osteoblasts. Fractions 7-9 and cells derived from bone particles were pooled and considered as osteocytes. After one passage, 8000 cells per well were seeded into collagen-coated 96-well plates (Greiner Bio-One, Kremsmünster, Austria) and treated with 1 μM 4-OHT for 3 days.
Co-culture experiments. BMCs were isolated from wild-type mice and 200 000 cells per well were added on top of primary osteocyte-enriched fractions or primary osteoblasts cultivated in co-culture medium (α-MEM supplemented with 10 nM 1,25-dihydroxyvitamin D3 (Sigma-Aldrich) and 20 ng/ml M-CSF). For pit assay, bone slices (Immunodiagnostic Systems, Tyne and Wear, UK) were used. Cells were removed from bone slices with 1 M ammonium hydroxide overnight and the resorption pits were visualized using 0.5% (w/v in H 2 O) toluidine blue.
For conditioned medium-transfer experiments, conditioned medium from Men1deficient primary osteocyte-enriched fractions or control primary osteocyte-enriched fractions was diluted 1:1 in co-culture medium.
